Clinical trials: Vulva Neoplasm
Cervical Cancer, Throat Cancer
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers.
- Conditions
- Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer
- Trial name
- NCT05686226
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Christian Hinrichs
Breast Carcinoma, Head and Neck Cancer
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
This is a single-center prospective clinical trial to evaluate non-inferiority of indocyanine green guided sentinel lymph node biopsy compared with the gold standard Technecium99 guided sentinel lymph node biopsy in patients with…
- Conditions
- Breast Carcinoma, Head and Neck Cancer, Melanoma (Skin), Squamous Cell Carcinoma, Skin
- Trial name
- GASVERT (NCT02997553)
- Testing
- Indocyanine green, Technetium99, Optonuclear probe
- Where
- France
- Volunteers
- 744 people
- Sponsor
- Institut de Cancérologie de Lorraine
Vulvar Cancers, Vulva Neoplasm
Needlefree Lidocaine Application for Vulvar Biopsies
The goal of this study is to compare pain during a vulvar biopsy using either the needle-free J-Tip device or the standard lidocaine shot.
- Conditions
- Vulvar Cancers, Vulva Neoplasm, Vulvar Dysplasia
- Trial name
- NCT07793552
- Testing
- J-Tip, Lidocaine HCl 1%
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
The goals of this prospective, observational cohort study are to determine the feasibility of implementing paclitaxel therapeutic drug monitoring for cancer patients and explore the relationship between paclitaxel drug exposure…
- Conditions
- Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Cervical Carcinoma
- Trial name
- NCT03987555
- Testing
- Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Wake Forest University Health Sciences
Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer
Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva
This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate.
- Conditions
- Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva
- Trial name
- NCT07672782
- Testing
- Tisotumab Vedotin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled.
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary
- Trial name
- NCT06730347
- Testing
- Lorigerlimab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- MacroGenics
Recurrent Vulvar Cancer, Persistent Vulvar Cancer
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.
- Conditions
- Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer
- Trial name
- PIERCE (NCT05903833)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 15 sites in Germany
- Volunteers
- 42 people
- Sponsor
- AGO Research GmbH
Vulva Cancer, Vulva Neoplasm
Danish Vulva Cancer Recurrence Study
The overall aim is to investigate different aspects of recurrence detection in women with vulva cancer (VC) to identify optimal treatment- and surveillance programs.
- Conditions
- Vulva Cancer, Vulva Neoplasm, Vulvar Cancer, Vulva Disease
- Trial name
- DaVulvaRec (NCT06495554)
- Testing
- Measurement of circulating tumor-DNA, Collection of patient-reported outcomes, Algorithmically determined telephone interview with a nurse
- Where
- 2 sites in Denmark
- Volunteers
- 1,295 people
- Sponsor
- University of Aarhus
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Vulva Cancer
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
MITO VULVA-1 is a prospective, single arm, multi-cohorts, phase II trial that aims to assess the activity and the safety of Lenvatinib plus Pembrolizumab in patients with vulvar cancer.
- Trial name
- MITO VULVA-01 (NCT07290894)
- Testing
- Pembrolizumab, Lenvatinib Capsules
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute, Naples
Tumor, Solid, Lung Cancer
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts anti-tumor effects by regulating the ferroptosis pathway.
- Conditions
- Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
- Trial name
- NCT07433283
- Testing
- Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron
- Where
- 9 sites in China
- Volunteers
- 54 people
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
Gynecologic Cancer, Endometrial Cancer
3D Printed Custom Applicators for HDR BT (DISCO)
Intracavitary brachytherapy for gynaecological cancer currently use cylinder-type applicators or custom wax moulds to place a radioactive source in close proximity to the treatment area and provide highly conformal dose…
- Conditions
- Gynecologic Cancer, Endometrial Cancer, Vaginal Cancer, Vulva Cancer
- Trial name
- NCT06432478
- Testing
- 3D-printed custom applicator
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Royal North Shore Hospital
Ovarian Cancer, Triple-Negative Breast Cancer
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer…
- Conditions
- Ovarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer, Cervical Cancer
- Trial name
- SCANDARE (NCT03017573)
- Testing
- Tumor biopsies / Tumor surgery, Blood withdrawal
- Where
- 6 sites in France
- Volunteers
- 1,050 people
- Sponsor
- Institut Curie
Vulva Cancer
SLN Mapping and ICG Dye for Vulvar Cancer
Doctors typically use blue dye to assist in locating and extracting lymph nodes for biopsy. However, this process can prove somewhat challenging for both patients and medical teams due to its need for extensive coordination and…
- Trial name
- NCT06035068
- Testing
- Indocyanine green
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tufts Medical Center
Vulva Cancer, Nurse Role
Simulation Supported Vulva Cancer and Self-Examination on Knowledge, Skills and Attitude
Objective: The aim of this study was to examine the effect of simulation-assisted vulvar cancer and vulva self-examination training on knowledge, skills and attitudes towards clinical practices.
- Trial name
- NCT07159958
- Testing
- Simulation-Based Vulvar Cancer and Self-Vulvar Examination Training
- Where
- Turkey (Türkiye)
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Trakya University
Paget Disease of the Vulva, Vulva Cancer
ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study
Patients with a new diagnosis or recurrence of high-grade squamous precancerous lesions or initially non-invasive vulvar Paget's disease, who have not undergone other types of treatment, will be considered at the Fondazione…
- Trial name
- NCT06715592
- Testing
- Bleomicina
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Tumor Recurrence, Malignant Epithelial Neoplasm of Vulva
Clinical Study on the Re-irradiation of Lateral Pelvic Recurrences of Gynecological Malignancies
The study aims to obtain a local control rate in patients with lateral pelvic relapses of gynecologycal cancers previously irradiated.
- Conditions
- Tumor Recurrence, Malignant Epithelial Neoplasm of Vulva, Malignant Epithelial Tumor of Ovary, Malignant Epithelial Neoplasm
- Trial name
- CYCLOPS (NCT05457595)
- Testing
- carbon ion radiation therapy
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Advanced Solid Tumor, Lung Cancer
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetics (PK) profile and preliminary efficacy of intratumoral injection of Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in patients with advanced…
- Conditions
- Advanced Solid Tumor, Lung Cancer, Pancreas Cancer, Breast Cancer
- Trial name
- CNSI-Fe(II) (NCT06048367)
- Testing
- CNSI-Fe(II) 30 mg, CNSI-Fe(II) 60 mg, CNSI-Fe(II) 90 mg
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN
Avelumab With Valproic Acid in Virus-associated Cancer
Up to 20% of all cancers may be associated with a bacterial or viral infection. In some instances, the infection may be one of the reasons why the cancer developed in the first place.
- Conditions
- Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva
- Trial name
- LATENT (NCT03357757)
- Testing
- Valproic Acid, Avelumab
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer, Prostate Cancer
Tempus Priority Study: A Pan-tumor Observational Study
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with…
- Conditions
- Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer
- Trial name
- NCT05179824
- Testing
- Observation
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Tempus AI